Perception Neuroscience
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
180 Varick St Fl 6, New York City, New Y...Website
www.perceptionns.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Perception Neuroscience
Perception Neuroscience is focused on transforming the approach to mental health by developing PCN-101 (Arketamine, or R-ketamine) aimed at providing enhanced solutions for serious mental health disorders. The company is dedicated to changing perceptions surrounding mental health treatment. Their target clients include individuals suffering from severe mental health issues. Through innovative research and development, they strive to improve the quality of life for those affected.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Perception Neuroscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Perception Neuroscience has new funding data
Click to see if Perception Neuroscience had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Perception Neuroscience
Earning: See what the market has to say on Perception Neuroscience recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Perception Neuroscience launches new products
Perception Neuroscience, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Perception Neuroscience is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Perception Neuroscience has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Perception Neuroscience as Masked Content
Find 3 more new buyers
Compare Similar Companies to Perception Neuroscience
Compare insights from companies similar to Perception Neuroscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Perception Neuroscience
<$5M
1-10
Private
-
2018
N/A
Company Profile Activity
Activity Insights
Perception Neuroscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Perception Neuroscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Perception Neuroscience.
Perception Neuroscience Tech Stack
A closer look at the technologies used by Perception Neuroscience
Perception Neuroscience News & Media
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, Perception Neuroscience’s Phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression Rating Scatai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
NEW YORK and BERLIN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropsychiatric diseases and its subsidiary, Perception Neuroscience (“Perception”), today announced the completion of enrollment of its Phase 2a clinical trial to evaluate the safety and efficacy of a single intravenous infusion (IV) dose of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of ketamine bein
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Perception Neuroscience
Sign Up For FreeTo access detailed company insights
Perception Neuroscience is focused on transforming the approach to mental health by developing PCN-101 (Arketamine, or R-ketamine) aimed at providing enhanced solutions for serious mental health disorders. The company is dedicated to changing perceptions surrounding mental health treatment. Their target clients include individuals suffering from se... Read More
